ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
Atavistik Bio
Atavistik Bio is seeking a Senior Director of Toxicology to lead and oversee all nonclinical safety studies supporting drug discovery and development. The role involves strategic leadership in toxicology, ensuring high-quality data for regulatory submissions, and collaboration across multiple scientific teams within a dynamic, high-growth biotech environment.
Headquarters
Cambridge, Massachusetts, United States
Company Size
11-50 employees
Founded
2021
Atavistik Bio is a clinical-stage biotechnology company focused on harnessing the power of allostery to develop transformative medicines. The company's approach enables selective modulation of disease-causing proteins, with lead asset ATV-1601, an oral allosteric AKT1-selective inhibitor being developed for Hereditary Hemorrhagic Telangiectasia (HHT), and a JAK2V617F mutant-selective inhibitor program for myeloproliferative neoplasms. Atavistik Bio aims to deliver best-in-class allosteric therapeutics to address serious unmet patient needs.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Atavistik Bio.
Atavistik Bio didn’t post a salary, so this is our estimate from similar listings.
Atavistik Bio Raises $120 Million Series B Financing to
Dec 18, 2025
